These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28254951)

  • 41. Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction.
    Yeo KP; Lowe SL; Lim MT; Voelker JR; Burkey JL; Wise SD
    Br J Clin Pharmacol; 2006 Feb; 61(2):200-10. PubMed ID: 16433874
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.
    Ayan-Oshodi MA; Willis BA; Annes WF; Lowe SL; Friedrich S; de la Peña A; Zhang W; Brown T; Wise SD; Hall SD
    Drug Metab Dispos; 2012 Oct; 40(10):1945-52. PubMed ID: 22789530
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone.
    McCune JS; Hawke RL; LeCluyse EL; Gillenwater HH; Hamilton G; Ritchie J; Lindley C
    Clin Pharmacol Ther; 2000 Oct; 68(4):356-66. PubMed ID: 11061575
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4.
    Zhang ZY; King BM; Pelletier RD; Wong YN
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):707-16. PubMed ID: 18431572
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A 96-well plate assay for CYP4503A induction using cryopreserved human hepatocytes.
    Kamiguchi N; Aoyama E; Okuda T; Moriwaki T
    Drug Metab Dispos; 2010 Nov; 38(11):1912-6. PubMed ID: 20699409
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quantitative Prediction of CYP3A4 Induction: Impact of Measured, Free, and Intracellular Perpetrator Concentrations from Human Hepatocyte Induction Studies on Drug-Drug Interaction Predictions.
    Sun Y; Chothe PP; Sager JE; Tsao H; Moore A; Laitinen L; Hariparsad N
    Drug Metab Dispos; 2017 Jun; 45(6):692-705. PubMed ID: 28336578
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prediction methods of drug-drug interactions of non-oral CYP3A4 substrates based on clinical interaction data after oral administrations - Validation with midazolam, alfentanil, and verapamil after intravenous administration and prediction for blonanserin transdermal patch.
    Tomita Y; Yahata M; Hashimoto M; Nishimuta H; Kawaguchi H; Matsushita H; Kitamura A; Nishibe H; Natsui K; Watanabe T
    Drug Metab Pharmacokinet; 2020 Aug; 35(4):345-353. PubMed ID: 32660818
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation.
    Foti RS; Rock DA; Wienkers LC; Wahlstrom JL
    Drug Metab Dispos; 2010 Jun; 38(6):981-7. PubMed ID: 20203109
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PF-1355, a mechanism-based myeloperoxidase inhibitor, prevents immune complex vasculitis and anti-glomerular basement membrane glomerulonephritis.
    Zheng W; Warner R; Ruggeri R; Su C; Cortes C; Skoura A; Ward J; Ahn K; Kalgutkar A; Sun D; Maurer TS; Bonin PD; Okerberg C; Bobrowski W; Kawabe T; Zhang Y; Coskran T; Bell S; Kapoor B; Johnson K; Buckbinder L
    J Pharmacol Exp Ther; 2015 May; 353(2):288-98. PubMed ID: 25698787
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam.
    Britz H; Hanke N; Volz AK; Spigset O; Schwab M; Eissing T; Wendl T; Frechen S; Lehr T
    CPT Pharmacometrics Syst Pharmacol; 2019 May; 8(5):296-307. PubMed ID: 30762305
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
    Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
    Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.
    Walsky RL; Obach RS; Hyland R; Kang P; Zhou S; West M; Geoghegan KF; Helal CJ; Walker GS; Goosen TC; Zientek MA
    Drug Metab Dispos; 2012 Sep; 40(9):1686-97. PubMed ID: 22645092
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Time-dependent inhibitory effects of (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxopropyl)-11,28-dioxa-4-azatricyclo[22.3.1.0(4.9)]octacos-18-ene-2,3,10,16-tetrone (FK1706), a novel nonimmunosuppressive immunophilin ligand, on CYP3A4/5 activity in humans in vivo and in vitro.
    Minematsu T; Lee J; Zha J; Moy S; Kowalski D; Hori K; Ishibashi K; Usui T; Kamimura H
    Drug Metab Dispos; 2010 Feb; 38(2):249-59. PubMed ID: 19889885
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity.
    Chen YC; Gotzkowsky SK; Nafziger AN; Kulawy RW; Rocci ML; Bertino JS; Kashuba AD
    Br J Clin Pharmacol; 2006 Aug; 62(2):187-95. PubMed ID: 16842393
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
    Tomkinson HK; Kemp JV; Wollseifen T; Morris T; Oliver SD
    Clin Ther; 2010 Jul; 32(7):1372-86. PubMed ID: 20678684
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro evaluation of cytochrome P450 induction and the inhibition potential of mitragynine, a stimulant alkaloid.
    Lim EL; Seah TC; Koe XF; Wahab HA; Adenan MI; Jamil MF; Majid MI; Tan ML
    Toxicol In Vitro; 2013 Mar; 27(2):812-24. PubMed ID: 23274770
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2.
    Rhodes SP; Otten JN; Hingorani GP; Hartley DP; Franklin RB
    J Pharmacol Toxicol Methods; 2011; 63(3):223-6. PubMed ID: 21111054
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults.
    Townsend R; Dietz A; Hale C; Akhtar S; Kowalski D; Lademacher C; Lasseter K; Pearlman H; Rammelsberg D; Schmitt-Hoffmann A; Yamazaki T; Desai A
    Clin Pharmacol Drug Dev; 2017 Jan; 6(1):44-53. PubMed ID: 27273461
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
    Yu Y; Loi CM; Hoffman J; Wang D
    J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
    Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
    J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.